Added to YB: 2024-01-29
Pitch date: 2024-01-28
ALDX [bullish]
Aldeyra Therapeutics, Inc.
+46.45%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
Market Cap
$303.8M
Pitch Price
$3.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.47
P/E
-7.00
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
$ALDX: Biotech w/ Reproxalap for dry eye & allergies, a RASP modulator reducing inflammation. FDA resubmission 1H24, $400M ABBV deal + 40% profits. $182M mkt cap < $144M cash = asymmetric risk/reward. Acq. potential. Strong buy.
Read full article (7 min)